5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Apr 4

PMID 35371346

Authors

Zhuoyuan Li

Siyu Wang

Yuxian Chen

Yaozhou Huang

Tianping Li

Affiliations

Soon will be listed here.

Abstract

The role of 5-methylcytosine-related long noncoding RNAs (m5C-lncRNAs) in bladder cancer (BLCA) remains unclear. Here, we aim to study the prognostic value, gene expression characteristics, and correlation between the m5C-lncRNA risk model and the tumor microenvironment, immune infiltration, and tumor mutations in BLCA. After collecting BLCA patient RNA sequence transcriptome data, clinical information and mutation data from the Cancer Genome Atlas (TCGA) database, 17 m5C-related lncRNAs independently correlated with OS were obtained by Lasso and multivariate Cox regression analysis, and a risk model was constructed. Univariate Cox, multivariate Cox regression analysis, and the C-index curve proved that the risk model was a significant independent prognostic indicator for patients with BLCA. ESTIMATE and CIBERSORT indicated that the higher the number of immune cells and stromal cells in TME, the higher the prognostic risk. We found that in the low-risk group, the expression levels of immune cells that predicted a good prognosis were higher, including plasma cells, regulatory T cells, and CD 8 T cells. There is a negative correlation between TMB and risk score. The TMB of the low-risk group is significantly higher than that of the high-risk group. In conclusion, the m5C-related risk model is crucial to predict the prognosis of patients with BLCA.

Citing Articles

Identification and validation of an m5C-related lncRNA signature for predicting prognosis and immune response in clear cell renal cell carcinoma.

Ao S, Liang L, Peng L, Yang R, Chen Z, Deng T Discov Oncol. 2025; 16(1):227.

PMID: 39987537 PMC: 11847763. DOI: 10.1007/s12672-025-01987-5.

The role of m5C RNA modification in cancer development and therapy.

Yu L, Xu H, Xiong H, Yang C, Wu Y, Zhang Q Heliyon. 2024; 10(19):e38660.

PMID: 39444404 PMC: 11497397. DOI: 10.1016/j.heliyon.2024.e38660.

Emerging role of RNA modification and long noncoding RNA interaction in cancer.

Yang L, Tang L, Min Q, Tian H, Li L, Zhao Y Cancer Gene Ther. 2024; 31(6):816-830.

PMID: 38351139 PMC: 11192634. DOI: 10.1038/s41417-024-00734-2.

The role of RNA modification in urological cancers: mechanisms and clinical potential.

Zhou X, Zhu H, Luo C, Yan Z, Zheng G, Zou X Discov Oncol. 2023; 14(1):235.

PMID: 38117350 PMC: 10733275. DOI: 10.1007/s12672-023-00843-8.

RNA m5C methylation orchestrates BLCA progression via macrophage reprogramming.

Yan D, Xie Y, Huang L, Zhang Y, Gu R, Xie H J Cell Mol Med. 2023; 27(16):2398-2411.

PMID: 37408139 PMC: 10424284. DOI: 10.1111/jcmm.17826.

References

Xuan W, Khan F, James C, Heimberger A, Lesniak M, Chen P . Circadian regulation of cancer cell and tumor microenvironment crosstalk. Trends Cell Biol. 2021; 31(11):940-950. PMC: 8526375. DOI: 10.1016/j.tcb.2021.06.008. View

Li Y, Yan B, Wang X, Li Q, Kan X, Wang J . ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9. J Cell Mol Med. 2021; 26(2):385-398. PMC: 8743647. DOI: 10.1111/jcmm.17091. View

Ontiveros R, Stoute J, Liu K . The chemical diversity of RNA modifications. Biochem J. 2019; 476(8):1227-1245. PMC: 9073955. DOI: 10.1042/BCJ20180445. View

Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J . Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa047. View

Bo C, Li N, He L, Zhang S, An Y . Long non-coding RNA ILF3-AS1 facilitates hepatocellular carcinoma progression by stabilizing ILF3 mRNA in an mA-dependent manner. Hum Cell. 2021; 34(6):1843-1854. DOI: 10.1007/s13577-021-00608-x. View

Jansson M, Hafner S, Altinel K, Tehler D, Krogh N, Jakobsen E . Regulation of translation by site-specific ribosomal RNA methylation. Nat Struct Mol Biol. 2021; 28(11):889-899. DOI: 10.1038/s41594-021-00669-4. View

Liu Q, Wu Y, Xiao J, Zou J . Long Non-Coding RNA Prostate Cancer-Associated Transcript 7 (PCAT7) Induces Poor Prognosis and Promotes Tumorigenesis by Inhibiting mir-134-5p in Non-Small-Cell Lung (NSCLC). Med Sci Monit. 2017; 23:6089-6098. PMC: 5749158. DOI: 10.12659/msm.907904. View

Tran L, Xiao J, Agarwal N, Duex J, Theodorescu D . Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2020; 21(2):104-121. PMC: 10112195. DOI: 10.1038/s41568-020-00313-1. View

Spaety M, Gries A, Badie A, Venkatasamy A, Romain B, Orvain C . HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers (Basel). 2019; 11(11). PMC: 6896094. DOI: 10.3390/cancers11111747. View

10.

Sun Z, Xue S, Zhang M, Xu H, Hu X, Chen S . Aberrant NSUN2-mediated mC modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene. 2020; 39(45):6906-6919. PMC: 7644462. DOI: 10.1038/s41388-020-01475-w. View

11.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

12.

Lang C, Dai Y, Wu Z, Yang Q, He S, Zhang X . SMAD3/SP1 complex-mediated constitutive active loop between lncRNA PCAT7 and TGF-β signaling promotes prostate cancer bone metastasis. Mol Oncol. 2020; 14(4):808-828. PMC: 7138406. DOI: 10.1002/1878-0261.12634. View

13.

Chen X, Li A, Sun B, Yang Y, Han Y, Yuan X . 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8):978-990. DOI: 10.1038/s41556-019-0361-y. View

14.

Chelmicki T, Roger E, Teissandier A, Dura M, Bonneville L, Rucli S . mA RNA methylation regulates the fate of endogenous retroviruses. Nature. 2021; 591(7849):312-316. DOI: 10.1038/s41586-020-03135-1. View

15.

Cui Y, Li F, Xie Q, Zhao S, Guo T, Guo P . YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC. Cell Death Dis. 2020; 11(6):476. PMC: 7305216. DOI: 10.1038/s41419-020-2555-4. View

16.

Squires J, Patel H, Nousch M, Sibbritt T, Humphreys D, Parker B . Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. Nucleic Acids Res. 2012; 40(11):5023-33. PMC: 3367185. DOI: 10.1093/nar/gks144. View

17.

Mossanen M . The Epidemiology of Bladder Cancer. Hematol Oncol Clin North Am. 2021; 35(3):445-455. DOI: 10.1016/j.hoc.2021.02.001. View

18.

Zhou H, Shi P, Jia X, Xue Q . Long non-coding RNA LINC01018 inhibits the progression of acute myeloid leukemia by targeting miR-499a-5p to regulate PDCD4. Oncol Lett. 2021; 22(1):541. PMC: 8157334. DOI: 10.3892/ol.2021.12802. View

19.

Liu H, Zou Y, Zhu W, Sen-Liu , Zhang G, Ma R . lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus. Cell Death Differ. 2021; 29(3):627-641. PMC: 8901790. DOI: 10.1038/s41418-021-00879-9. View

20.

Zhou J, Zhang S, Luo M . LncRNA promotes the malignant progression of breast cancer by regulating ErbB/PI3K/Akt pathway. Future Oncol. 2021; 17(6):701-710. DOI: 10.2217/fon-2020-0273. View